Literature-reported formulation composition
Component: 93-O17S | Reported mass ratio (w/w): 16 | Role: Ionizable lipid
sales@dcchemicals.com
93-O17S
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | Reported mass ratio (w/w): 4 | Role: Sterol
Literature-reported formulation composition
Component: DOPE | Reported mass ratio (w/w): 1 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Reported ratio sum | Reported mass ratio (w/w): 21 | Role: Original ratio retained
Table 2
Experiment: cGAMP delivery | Study condition: RAW264.7 and DC2.4; 4 h | Reported result: Cytosolic distribution; 85% cGAMP-Fluo encapsulation
Table 2
Experiment: OVA vaccination | Study condition: Prime/boost on days 1 and 14 | Reported result: ~1.8% OVA-specific CD8+ T cells with cGAMP
Table 2
Experiment: Tumor therapy | Study condition: DOX day 0; 93-O17S-F/cGAMP days 1 and 5 | Reported result: 2/7 mice tumor-free by day 30
Reported observation
Literature-reported cGAMP-Fluo encapsulation 85% 93-O17S-F/cGAMP-Fluo Primary article Methods, Cellular uptake of cGAMP
Reported observation
Literature-reported ifnb1 expression 6.9-fold (RAW264.7) and 6.4-fold (DC2.4) versus PBS 93-O17S-F/cGAMP; 4 h; n=6 Primary article Results, Fig. 3C
Reported observation
Literature-reported cxcl10 expression >100-fold versus PBS 93-O17S-F/cGAMP; 4 h; n=6 Primary article Results, Fig. 3D
Reported observation
Literature-reported OVA-specific CD8+ T cells ~1.4% without cGAMP and ~1.8% with cGAMP Spleen after prime-boost OVA vaccination; n=3 Primary article Results, Fig. 4B
Reported observation
Literature-reported OVA-specific target-cell killing ~60% without cGAMP and ~70% with cGAMP In vivo cytotoxic T-cell assay; n=2 Primary article Results, Fig. 4C
Reported observation
Literature-reported B16F10 tumor eradication 2/7 mice (28.6%) tumor-free by day 30 DOX pretreatment + intratumoral 93-O17S-F/cGAMP on days 1 and 5 Primary article Results, Fig. 6C-E
Reported observation
Antigen capture 93-O17S-F changed size and zeta potential after mixing with tumor lysate and delivered model antigen to draining lymph nodes in vivo. Protein/tumor-lysate capture experiments · Primary article Results, Fig. 5 and cited Supplementary Figs. S5-S6
Reported observation
Combination dependence 93-O17S-F/cGAMP without DOX pretreatment produced only modest tumor inhibition; the strongest effect required prior DOX-induced antigen release. B16F10 model · Primary article Results, Fig. 6
Reported observation
Rechallenge Among mice that recovered from the primary tumor and were rechallenged, 71% were tumor-free 30 days after rechallenge. Selected primary-tumor responders; n=7 rechallenge · Primary article Results, Fig. 6G